LOGIN  |  REGISTER
Astria Therapeutics

Gamida Cell (NASDAQ: GMDA) Stock Quote

Last Trade: US$0.03
Volume: 0
5-Day Change: -9.42%
YTD Change: -92.08%
Market Cap: US$4.340M

Latest News From Gamida Cell

Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge ® (omidubicel-onlv) Gamida Cell to become a private company under ownership of Highbridge following Israeli court approval BOSTON and NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful... Read More
Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge ® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding Company to host conference call today at 8:30 a.m. ET BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells... Read More
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024. Following the release, management will host a conference call and live webcast at... Read More
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel-onlv) Preliminary data presented on GDA-201, Gamida Cell’s natural killer (NK) cell therapy candidate in ongoing Phase 1 study for non-Hodgkin lymphoma, show promising early evidence of anti-tumor activity BOSTON, Feb. 23, 2024... Read More
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction. However, there can be no assurance that the company’s strategic alternatives process will result in... Read More
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA approved allogeneic stem cell therapy Omisirge ® (omidubicel-onlv) and allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of... Read More
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles. Dr. Schiller will... Read More
BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35 th Annual Healthcare Conference in New York, NY. Presentation Details Format: Fireside Chat Date/Time: Tuesday, November 28, 2023 at 11:00 –11:25 AM ET Webcast: Click here... Read More
Company continues to advance launch, reports initial revenue from Omisirge ® (omidubicel-onlv) Company to host conference call today at 8:30 a.m. ET BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update. “The third quarter... Read More
BOSTON, Nov. 04, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting... Read More
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern... Read More
Data show promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma Full data readout of Phase 1 study expected in Q1 2024 BOSTON--( BUSINESS WIRE )-- Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new early data in 10 patients with CD20 positive non-Hodgkin lymphoma enrolled in the first three... Read More
BOSTON / Oct 09, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today issued an update on its operations in Israel. “We remain profoundly saddened by the attacks in Israel this weekend and express our deepest condolences to the people of Israel as they mourn the loss of loved ones and defend themselves,” said Abbey Jenkins, President and Chief... Read More
Abbey Jenkins, President and Chief Executive Officer, to also participate in the panel “A record setting year for cell and gene therapies – how do we keep the momentum going?” BOSTON / Oct 02, 2023 / Business Wire / Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate... Read More
BOSTON / Sep 28, 2023 / Business Wire / Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it will be presenting at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023) taking place in San Diego, CA and virtually November 1-5, 2023. Details about the poster presentations are as follows: Title : GDA-201, nicotinamide (NAM)... Read More
Omisirge is the only allogeneic stem cell therapy approved by the U.S. Food and Drug Administration (FDA) on the basis of a global randomized Phase 3 trial Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress BOSTON / Sep 27, 2023 / Business Wire / Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that... Read More
BOSTON / Aug 31, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming H.C. Wainwright 25 th Annual Global Investment Conference in New York, NY. Presentation Details Format: Fireside chat Date and time: Available on-demand Monday, September 11, 2023, at 7 a.m.... Read More
Strong start for Omisirge ® (omidubicel-onlv) launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further support Omisirge launch Cash runway extended into Q2 2024; balance sheet strengthened with $9 million reduction in debt Company to host conference call today at 8:30 a.m. ET BOSTON / Aug 14, 2023 / Business Wire /... Read More
Conference Call and Webcast Scheduled for Monday, August 14 th at 8:30 am Eastern Time BOSTON / Aug 01, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. Following the release, management will host a conference... Read More
Faster immune reconstitution and decreased rate of post-transplant viral infection in patients transplanted with Omisirge versus umbilical cord blood BOSTON / Jul 11, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the publication in press of a prospective sub-study of the Phase 3 clinical trial for Omisirge ® (omidubicel-onlv),... Read More
HealthStocksHub
Veteran Oncology Researcher to Guide Investment in Breakthrough Cancer Treatments LOS ANGELES , July 10, 2023 /PRNewswire/ -- Stand Up To Cancer ® (SU2C) today announced that Julian Adams, Ph.D., a longtime oncology researcher and retired pharmaceutical industry chief executive, was named the organization's first Chief Science... Read More
Thought leaders Dr. Steven Devine and Dr. Usama Gergis to share perspectives on unmet needs and the clinical landscape in stem cell transplant Update on the progress of the commercial launch for Omisirge ® to be provided BOSTON / Jun 14, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, will host an Investor Day on Thursday, June 29, 2023... Read More
BOSTON / May 31, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET. Ms. Korfin’s presentation will include an overview of the company’s corporate... Read More
New data for batch-to-batch variability and cytotoxicity of GDA-201 show long term stability and unique phenotype of allogeneic NAM-NK cell therapy GDA-201 is in an ongoing Phase 1/2 clinical trial for non-Hodgkin lymphoma BOSTON / May 31, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting... Read More
Industry veteran Coelho brings more than 35 years of experience at emerging growth and global companies to role; Shai Lankry to leave company June 2 BOSTON / May 22, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately. Shai Lankry, who has served as the... Read More
Company reports positive feedback and continued progress on transplant center onboarding and payer coverage around launch of Omisirge ® (omidubicel-onlv), a new cell therapy for allogeneic stem cell transplant approved April 17 by the FDA Company successfully completed public offering, raising gross proceeds of $22.8 million Company reports positive momentum on two-pronged corporate strategy: executing commercial plan and... Read More
BOSTON / May 11, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised... Read More
BOSTON / Apr 19, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share and accompanying warrant, for gross proceeds of approximately $22.8... Read More
BOSTON / Apr 18, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be... Read More
Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and fungal infections as compared to standard cord blood Omisirge may increase access to stem cell transplant, including among patients from diverse backgrounds Conference call April 18 at 8 am ET BOSTON / Apr 17, 2023 / Business Wire /... Read More
Company reports on productive interactions with FDA and preparations for launch of omidubicel, if approved, in advance of May 1 PDUFA date Company outlines strategic restructuring, plans to prioritize omidubicel launch and reduce operating expenses to extend cash runway Company to explore strategic options to support a broader launch of omidubicel, including potential US and global partnerships with pharmaceutical companies... Read More
BOSTON / Mar 20, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately. “On behalf of my fellow board members and Gamida Cell’s employees, I want to thank Robert for his dedicated service to this... Read More
BOSTON / Mar 20, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial results and provide an update on the company. To access the conference call, please register here... Read More
BOSTON / Mar 07, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the upcoming Oppenheimer 33 rd Annual Healthcare Conference on March 14 th , 2023 at 9:20 a.m. ET. Ms. Jenkins will discuss company updates, including preparations... Read More
BOSTON / Feb 18, 2023 / Business Wire / Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that two oral presentations and a poster presentation highlighting Gamida Cell’s investigational product candidates, omidubicel and GDA-201, were shared at the 2023 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB